IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8975286 B1

PDFFull Text
Date of Patent:
Mar. 10, 2015

Filed:

Aug. 16, 2010

Ether benzotriazole derivatives

Applicants:

Vadim Y. Dudkin, West Point, PA (US);

Mark E. Fraley, West Point, PA (US);

Cheng Wang, West Point, PA (US);

Robert M. Garbaccio, West Point, PA (US);

Douglas C. Beshore, West Point, PA (US);

Scott K. Kuduk, West Point, PA (US);

Jason W. Skudlarek, West Point, PA (US);

Inventors:

Vadim Y. Dudkin, West Point, PA (US);

Mark E. Fraley, West Point, PA (US);

Cheng Wang, West Point, PA (US);

Robert M. Garbaccio, West Point, PA (US);

Douglas C. Beshore, West Point, PA (US);

Scott K. Kuduk, West Point, PA (US);

Jason W. Skudlarek, West Point, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Keith D. MacMillan

John C. Todaro

Primary Examiner:

Joseph Kosack

Assistant Examiner:

Matthew Coughlin

Int. Cl.
CPC ...
C07D 409/14 (2006.01); C07D 405/14 (2006.01); C07D 401/14 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 249/18 (2006.01); A61K 31/506 (2006.01); A61K 31/497 (2006.01); A61K 31/496 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/444 (2006.01); A61K 31/4439 (2006.01); A61K 31/4192 (2006.01); C07D 417/14 (2006.01); C07D 403/14 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 487/08 (2006.01); C07D 487/10 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/4439 (2013.01); A61K 31/4192 (2013.01); A61K 31/454 (2013.01); A61K 31/444 (2013.01); A61K 31/497 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/496 (2013.01); C07D 249/18 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/10 (2013.01); C07D 495/04 (2013.01);
Abstract

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Find Patent Forward Citations

Loading…